Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 3711.

https://doi.org/10.1182/blood-2025-3711

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience

Tatiana Novichkova, Natalia Orlov, Ronit Marcus, Ohad Benjamini, Yulia Volchek, Elena Ribakovsky, Meirav Kedmi, Liat Shargian, Drorit Merkel, Abraham Avigdor, Irina Amitai

Blood (2025) 146 (Supplement 1): 6863.

https://doi.org/10.1182/blood-2025-6863

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.

Avichai Shimoni, Noga Shem-Tov, Ronit Yerushalmi, Ivetta Danylesko, Alexandra Tsynman, Yulia Volchek, Abraham Avigdor, Arnon Nagler

Blood (2025) 146 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2025-6054

Published: 2025

Journal Articles

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study

Liat Shargian, Maya Zlotnick, Ron Ram, Odelia Amit, Adi Sherban, Ofir Wolach, Adi Schacham Abulafia, Boaz Nachmias, Chezi Ganzel, Drorit Merkel, Meirav Kedmi, Abraham Avigdor, Irina Amitai

Blood (2025) 146 (Supplement 1): 6969.

https://doi.org/10.1182/blood-2025-6969

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study

Blood (2025) 146 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2025-3618

Published: 2025

Journal Articles

Treosulfan – based conditioning in allogeneic hematopoietic stem-cell transplantation for lymphoid malignancies: Long term follows up.

Avichai Shimoni, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Alexandra Tsynman, Abraham Avigdor, Arnon Nagler

Blood (2025) 146 (Supplement 1): 5983.

https://doi.org/10.1182/blood-2025-5983

Published: 2025

Journal Articles

Point of care anti-CD19 CAR-T for autoimmune diseases

Ronit Marcus, Merav Lidar, Doron Rimar, Elad Jacoby, Orit Itzhaki, Jonathan Esensten, Avichai Shimoni, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Abraham Avigdor

Blood (2025) 146 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2025-5946

Published: 2025

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Neha Dixit, Binhuan Wang, Kevin Zhao, Catherine Thieblemont, Irit Avivi Mazza, David Lavie, Abraham Avigdor, Carlos Grande Garcia, Andrew J. Steele, Mostafa Seliem, Pegah Jafarinasabian, Edith Szafer Glusman

Blood (2024) 144 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2024-200395

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Shlomzion Aumann, Abraham Avigdor, Ronit Marcus, Netanel A. Horowitz, Ronit Gurion, Tamar Tadmor, Roy Vitkon, May Meira Basood, Uri Abadi, Meirav Kedmi

Blood (2024) 144 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2024-198926

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study

Treosulfan – based conditioning in allogeneic hematopoietic stem-cell transplantation for lymphoid malignancies: Long term follows up.

Point of care anti-CD19 CAR-T for autoimmune diseases

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only